Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in Fontan-palliated adults and adolescents
2016-003320-23Phase 3Unknown
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Single Ventricle Heart Defects, Fontan circulation and Cardiovascular Malformation (CVM) comparing Macitentan with Placebo (2 arms). Primary endpoints: Change in peak VO2 and Change in long-term peak VO2 over 52 weeks. Status: unknown.
02
Drugs
macitentan
03
Conditions
Single Ventricle Heart DefectsFontan circulationCardiovascular Malformation (CVM)
Beyond the preview
Go deeper on 2016-003320-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003320-23.